Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia. - Beck-Nielsen SS; Ariceta G; Boot AM; Brandi ML; Briot K; de Lucas Collantes C; Emma F; Giannini S; Haffner D; Keen R; Levtchenko E; Nilsson O; et al. (European journal of endocrinology, 2026)